CN116056701A - 治疗结节硬化复合症的方法 - Google Patents

治疗结节硬化复合症的方法 Download PDF

Info

Publication number
CN116056701A
CN116056701A CN202180057592.9A CN202180057592A CN116056701A CN 116056701 A CN116056701 A CN 116056701A CN 202180057592 A CN202180057592 A CN 202180057592A CN 116056701 A CN116056701 A CN 116056701A
Authority
CN
China
Prior art keywords
compound
formula
pharmaceutically acceptable
acceptable salt
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180057592.9A
Other languages
English (en)
Chinese (zh)
Inventor
G·加里波帝
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Noema Pharma AG
Original Assignee
Noema Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Noema Pharma AG filed Critical Noema Pharma AG
Publication of CN116056701A publication Critical patent/CN116056701A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Fruits And Vegetables (AREA)
CN202180057592.9A 2020-06-05 2021-06-04 治疗结节硬化复合症的方法 Pending CN116056701A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063035313P 2020-06-05 2020-06-05
US63/035313 2020-06-05
PCT/EP2021/065075 WO2021245281A1 (en) 2020-06-05 2021-06-04 Methods of treatment of tuberous sclerosis complex

Publications (1)

Publication Number Publication Date
CN116056701A true CN116056701A (zh) 2023-05-02

Family

ID=76325558

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180057592.9A Pending CN116056701A (zh) 2020-06-05 2021-06-04 治疗结节硬化复合症的方法

Country Status (13)

Country Link
US (3) US11684613B2 (https=)
EP (1) EP4161512A1 (https=)
JP (2) JP2023528895A (https=)
KR (2) KR20230027145A (https=)
CN (1) CN116056701A (https=)
AU (1) AU2021285273A1 (https=)
BR (1) BR112022024760A2 (https=)
CA (1) CA3180794A1 (https=)
CL (1) CL2022003435A1 (https=)
IL (2) IL322310A (https=)
MX (1) MX2022015407A (https=)
PH (1) PH12023550016A1 (https=)
WO (1) WO2021245281A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022024760A2 (pt) * 2020-06-05 2023-03-07 Noema Pharma Ag Métodos de tratamento do complexo de esclerose tuberosa
EP4658268A1 (en) * 2023-02-02 2025-12-10 Noema Pharma AG Methods of treatment of dravet syndrome

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1802367A (zh) * 2003-06-05 2006-07-12 弗·哈夫曼-拉罗切有限公司 作为谷氨酸受体拮抗剂的咪唑衍生物
CN101568531A (zh) * 2006-12-21 2009-10-28 弗·哈夫曼-拉罗切有限公司 Mglur5受体拮抗剂的多晶型物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ551253A (en) 2004-06-01 2010-07-30 Hoffmann La Roche Pyridin-4-yl-ethynyl-imidazoles and pyrazoles as MGLU5 receptor antagonists
US8211882B2 (en) 2008-03-08 2012-07-03 Richard Delarey Wood Glutamate receptor modulators and therapeutic agents
US20120040008A1 (en) * 2010-08-11 2012-02-16 Ashish Chatterji Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
US20120039999A1 (en) 2010-08-11 2012-02-16 Ashish Chatterji Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
BR112022024760A2 (pt) * 2020-06-05 2023-03-07 Noema Pharma Ag Métodos de tratamento do complexo de esclerose tuberosa

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1802367A (zh) * 2003-06-05 2006-07-12 弗·哈夫曼-拉罗切有限公司 作为谷氨酸受体拮抗剂的咪唑衍生物
CN101568531A (zh) * 2006-12-21 2009-10-28 弗·哈夫曼-拉罗切有限公司 Mglur5受体拮抗剂的多晶型物

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
E.KELLY等: "mGluR5 modulation of behavioural and epileptic phenotypes in a mouse model of tuberous sclerosis complex", 《NEUROPSYCHOPHARMACOLOGY》, vol. 43, no. 6, 5 December 2017 (2017-12-05), pages 1457 - 1465, XP036968571, DOI: 10.1038/npp.2017.295 *
FOWLER, S等: "Low Potential of Basimglurant to Be Involved in Drug-Drug Interactions: Influence of Non-Michaelis-Menten P450 Kinetics on Fraction Metabolized", 《JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS》, vol. 360, no. 1, 15 December 2016 (2016-12-15), pages 164 - 173, XP055830181, DOI: 10.1124/jpet.116.237214 *
NICKOLS, HH等: "Development of allosteric modulators of GPCRs for treatment of CNS disorders", 《NEUROBIOLOGY OF DISEASE》, vol. 61, 27 September 2013 (2013-09-27), pages 55 - 71, XP028780046, DOI: 10.1016/j.nbd.2013.09.013 *
S.N.ISHERWOOD等: "Bidirectional variation in glutamate efflux in the medial prefrontal cortex induced by selective positive and negative allosteric mGluR5 modulators", 《JOURNAL OF NEUROCHEMISTRY》, vol. 145, no. 2, 12 February 2018 (2018-02-12), pages 111 - 124, XP055830170, DOI: 10.1111/jnc.14290 *
曹淑忠等: "挤出滚圆法制备盐酸索他洛尔骨架缓释微丸", 《药学研究》, vol. 32, no. 03, 15 March 2013 (2013-03-15), pages 162 - 164 *

Also Published As

Publication number Publication date
AU2021285273A1 (en) 2023-01-19
CA3180794A1 (en) 2021-12-09
IL298709A (en) 2023-02-01
US20230100520A1 (en) 2023-03-30
JP2025122066A (ja) 2025-08-20
PH12023550016A1 (en) 2024-03-11
US20230277513A1 (en) 2023-09-07
US11998535B2 (en) 2024-06-04
JP2023528895A (ja) 2023-07-06
BR112022024760A2 (pt) 2023-03-07
KR20250116184A (ko) 2025-07-31
US20250099445A1 (en) 2025-03-27
US11684613B2 (en) 2023-06-27
IL322310A (en) 2025-09-01
EP4161512A1 (en) 2023-04-12
MX2022015407A (es) 2023-05-16
WO2021245281A1 (en) 2021-12-09
CL2022003435A1 (es) 2023-10-20
KR20230027145A (ko) 2023-02-27

Similar Documents

Publication Publication Date Title
MXPA05002549A (es) Cristal para un farmaco oral solido y farmaco oral solido que lo contiene para el tratamiento de la disuria.
JP2025122066A (ja) 結節性硬化症の治療の方法
EA029180B1 (ru) Лекарственная форма лакозамида для приема один раз в сутки
JP2008542419A (ja) 神経刺激性ステロイドの医薬組成物及びその使用
KR102515847B1 (ko) 융합된 트리사이클릭 감마-아미노산 유도체의 조성물 및 이의 제조 방법
CN101896477B (zh) 硝克柳胺化合物晶v型、其制法和其药物组合物与用途
EP2314569A1 (en) Novel polymorphic forms of (S)-2-[4-(3-Fluoro-benzyloxy)-benzylamino]-propionamide mesylate salt and processes of manufacturing thereof
JP5571072B2 (ja) アルファアドレナリン介在症状の治療方法
CN113214209A (zh) 橙皮素与卡马西平共晶物及制备方法和其组合物与用途
JP2020528881A (ja) フェノラミンｇ型結晶、その製造方法並びにその組成物及び用途
JP2023528895A5 (https=)
CN109721557B (zh) 来曲唑晶ii型固体物质及制备方法和其药物组合物与用途
CN115989024A (zh) 治疗三叉神经痛的方法
OA21484A (en) Methods of treatment of tuberous sclerosis complex.
CN114524769B (zh) 塞来昔布-卡马西平共晶、制备方法、药物组合物和应用
CN109721558B (zh) 来曲唑晶iii型固体物质及制备方法和其药物组合物与用途
OA21124A (en) Methods of treatment of trigeminal neuralgia.
EA045716B1 (ru) Композиция конденсированных трициклических производных гамма-аминокислоты для лечения и/или предупреждения механической боли и её приготовление
CN106491592A (zh) 土木香内酯衍生物及其盐在制备治疗甲状腺炎药物中的应用
HK1084396B (en) Crystal for oral solid drug and oral solid drug for dysuria treatment containing the same

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination